Triazolam tablets contain triazolam, a triazolobenzo-diazepine hypnotic agent. Triazolam is a white crystalline powder, soluble in alcohol and poorly soluble in water.
Triazolam tablets are indicated for the short-term treatment of insomnia (generally 7 to 10 days). Use for more than 2 to 3 weeks requires complete reevaluation of the patient (see WARNINGS).
Prescriptions for triazolam should be written for short-term use (7 to 10 days) and it should not be prescribed in quantities exceeding a 1-month supply.
Media Articles Related to Triazolam
Insomnia linked to higher risk of death
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2013.11.22]
A new study of men by researchers from Brigham and Women's Hospital in Boston, MA, has found that some insomnia symptoms are linked to a higher risk of death.
Insomnia Cure Boosts Success of Depression Treatment, Study Finds
Source: MedicineNet Depression Specialty [2013.11.20]
Title: Insomnia Cure Boosts Success of Depression Treatment, Study Finds
Category: Health News
Created: 11/19/2013 4:36:00 PM
Last Editorial Review: 11/20/2013 12:00:00 AM
Prescription Sleep Aids a Common Choice for American Insomnia
Source: MedicineNet temazepam Specialty [2013.08.29]
Title: Prescription Sleep Aids a Common Choice for American Insomnia
Category: Health News
Created: 8/29/2013 9:35:00 AM
Last Editorial Review: 8/29/2013 12:00:00 AM
10 Tips to Avoid Insomnia and Get a Good Night's Sleep
Source: MedicineNet alprazolam Specialty [2012.08.07]
Title: 10 Tips to Avoid Insomnia and Get a Good Night's Sleep
Category: Doctor's Views
Created: 6/14/2005 12:00:00 AM
Last Editorial Review: 8/7/2012 12:00:00 AM
Source: MedicineNet Creutzfeldt-Jakob Disease Specialty [2012.02.07]
Category: Diseases and Conditions
Created: 6/6/2005 12:00:00 AM
Last Editorial Review: 2/7/2012 12:00:00 AM
Published Studies Related to Triazolam
Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women. [2011.06]
RATIONALE: Gender plays a critical role in the effects of drugs and drug abuse liability. Biological factors, including ovarian hormones, may contribute to gender differences in drug abuse. Preclinical and some clinical research suggests that progesterone and its metabolites have activity at the GABA(A) receptor and may enhance the effect of GABAergic compounds (e.g., benzodiazepines). Because women are exposed to varying levels of progesterone from puberty until menopause, and appear more sensitive to the negative consequences of benzodiazepine use, it is important to understand the impact of progesterone on GABAergic drug effects. OBJECTIVES: The purpose of this experiment was to characterize the behavioral effects of progesterone, alone and in combination with the short-acting benzodiazepine, triazolam, to determine if progesterone potentiates the behavioral effects of triazolam... CONCLUSIONS: Progesterone potentiates the behavioral effects of benzodiazepines and may contribute to benzodiazepine use and abuse among women.
Dose effects of triazolam and scopolamine on metamemory. [2010.02]
The present study compared the acute dose effects of the benzodiazepine triazolam and the anticholinergic scopolamine on metamemory (knowledge and awareness of one's own memory) in a two-phase paradigm designed to assess effects on both monitoring and control components of metamemory in both semantic (general knowledge) and episodic memory (cued-recall) tasks...
Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial. [2009.05]
BACKGROUND: Incremental sublingual (SL) dosing of triazolam has emerged as a popular sedation technique. Nevertheless, few studies have evaluated the technique's safety or efficacy. Given its popularity, an easily administered rescue strategy is needed... CONCLUSIONS: Deep sedation from incremental SL dosing of triazolam is incompletely reversed by a single intraoral injection of flumazenil. The reversal did not persist. The authors discharged the patients from the dental clinic at 360 minutes. CLINICAL IMPLICATIONS: A single intraoral injection of flumazenil (0.2 mg) cannot immediately reverse oversedation with triazolam. A higher dose might be effective. Reversal for the purpose of discharging the patient early is neither appropriate nor safe.
Modulation of the discriminative stimulus effects of triazolam across the menstrual cycle phase in healthy pre-menopausal women. [2008.04.01]
Pre-clinical studies indicate that changes in progesterone levels across menstrual cycle phases modulate the behavioral effects of sedative drugs acting at GABA(A) receptor sites. In this study, seven healthy women learned to discriminate triazolam (0.25 mg/70 kg) from placebo... These results suggest that the discriminative stimulus effects of the positive GABA(A) modulator, triazolam, are sensitive to menstrual cycle phase in healthy adult women.
Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. [2006.11]
Although preclinical studies suggest that GHB has low likelihood for abuse, case reports indicate that GHB is abused. This study evaluated the relative abuse liability of GHB in 14 volunteers with histories of drug abuse... Although the likelihood for GHB to be abused is intermediate to triazolam and pentobarbital, the possibility of accidental overdose (ie greater sedation than intended) with GHB appears to be greater.
Clinical Trials Related to Triazolam
A Study of the Acute Behavioral and Subjective Effects of TAK-375 [Completed]
This study focused on the drug abuse potential of TAK-375 16 mg, TAK-375 80 mg and TAK-375
160 mg compared to triazolam 0. 25 mg, triazolam 0. 50 mg, triazolam 0. 75 mg, alprazolam and a
placebo, each taken once over an eight day period in subjects with a history of polydrug
A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Adults and Healthy Elderly Participants [Not yet recruiting]
The primary purpose of the study is to evaluate the pharmacokinetics (what the body does to
the medication) of intranasally (through the nose) administered esketamine in healthy adult
and elderly participants.
Physiological, Behavioral and Subjective Effects of Drugs (GHB) [Recruiting]
The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid
(GHB) by comparing its physiological, behavioral and subjective effects with those of several
Flumazenil Reversal of Oral Triazolam [Completed]
An increase in the utilization of anesthesia and sedation medications by
non-anesthesiologists, including dentists, has grown dramatically. This has been prompted,
in part, by the need for pharmacological tools to address high levels of fear and anxiety
about dental care among the US population and the evidence of oral health disparities among
those who are fearful . Given the prevalence of dental fear in the general population and in
the various populations with the greatest burden of oral diseases, effective sedation
techniques are needed that are safe and effective in the hands of general dentists that make
up the "front line" in the efforts to reduce oral health disparities. This study is to
determine whether, when compared to a saline placebo, a single intraoral submucosal
administration of the benzodiazepine antagonist flumazenil (0. 2 mg) is capable of attenuating
in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of
stacked sublingual dosing of triazolam (3 doses of 0. 25 mg over 90 minutes).
Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine [Completed]
Cocaine abuse continues to represent a significant public-health concern. Cocaine likely
creates its addictive effects by increasing levels of dopamine, a chemical found in the
brain. GABA agonists are chemicals that have the opposite effect of cocaine by inhibiting the
release of dopamine. The purpose of this study is to determine whether GABA agonists reduce
the psychological and physiological reinforcing effects of cocaine.
Reports of Suspected Triazolam Side Effects
Drug Ineffective (23),
Intentional Overdose (4),
Stevens-Johnson Syndrome (4),
Maternal Exposure During Pregnancy (4),
Ventricular Tachycardia (4),
Pain (3), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Triazolam has an overall score of 4. The effectiveness score is 8 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
Triazolam review by 48 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Sedation Dentistry for dental implants|
|Dosage & duration:|| || 2-4 250 mg before each session taken varried - 1-3 times a month for 6 months for the period of 6 months|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Made dental implants possible|
|Side effects:|| || The triazolam seemed to stay in my system for days. I experienced a moderate degree of memory loss. There were also a couple instances of loss of cognitive reasoning, which was most frightening.|
|Comments:|| || I had total dental implants, which involved removing my existing deteriorating teeth (full set) and then placing first, temporary titanium posts into my upper and lower jaws and then permanent posts. A series of temporary acrylic "teeth" were fashioned to fit onto the temporary and permanent posts until my gums healed. Then permanent porcelain teeth were attached to the implant posts.|
Page last updated: 2013-11-22